Carsten Niemann

2:02
Monoallelic TP53-mutated CLL patients show durable response to ibrutinib monotherapy
Carsten Niemann
2:04
Understanding risk factors for Ritcher’s transformation: addressing the unmet need
Carsten Niemann
3:33
Death from infection: reducing the risk in patients with CLL
Carsten Niemann
2:21
Promising results from the HOVON-141 trial for CLL
Carsten Niemann
2:01
PHILEMON: a step closer to using MRD to guide treatment decisions in mantle cell lymphoma (MCL)?
Carsten Niemann
2:16
How to treat a previously treated CLL patient
Carsten Niemann
2:31
Use of novel algorithms based on pattern recognition to identify patients in need of CLL treatment
Carsten Niemann
2:03
What we are learning about CLL treatments and the microenvironment
Carsten Niemann
1:13
Guidance on how to prevent infections in patients with CLL
Carsten Niemann
1:44
Upcoming CLL trials on treatment options
Carsten Niemann
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals